COPD: Pulmonary Rehab is Effective Regardless of Inhaled Triple Therapy Use
September 15, 2022

In-hospital pulmonary rehabilitation improves function and symptoms in COPD patients whether they are on triple therapy or not, a new study confirms.

Smaller Airway Structures Raise Risk for COPD in Women, According to New Research
August 08, 2022

Lung airways were smaller in women than men, even among ever-smokers and never-smokers, according to large analysis.

Delay in IPF Diagnosis Led to Decreased Progression-free Survival, Increased Hospitalization
August 03, 2022

A real-world study found that a delay in diagnosis of 1 year or more was particularly detrimental to patients with mild disease at time of diagnosis.

Inhaler Education with Teach-to-Goal Methods Improved Technique Among Older Adults with Asthma, COPD
August 02, 2022

Additional research into tailored metered-dose inhaler education is needed, according to authors of a recent study.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
May 20, 2022

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Review of Biologic Treatments for Asthma Finds Inconsistent Effects on Airway Hyperresponsiveness
May 19, 2022

ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.

Tezepelumab Reduces Asthma Exacerbations by More than Half, Reports NAVIGATOR Study Author
May 19, 2022

Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.

Real-world Data Showed Mepolizumab Reduced Exacerbations, Oral Corticosteroid Use in Adults with Severe Asthma
May 18, 2022

ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.

Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim
May 17, 2022

ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.

NAVIGATOR Data Presented at ATS 2022 Show Improved Clinical Responses to Treatment with Tezepelumab vs Placebo
May 16, 2022

ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.